Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer | Synapse

December 7, 2011Open Access

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Baselga et al. (Wed,) studied this question.

synapsesocial.com/papers/69dff5e12833447a7e2556a4 https://doi.org/https://doi.org/10.1056/nejmoa1109653

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1mTOR and cancer: many loops in one pathway2009 · 419 citations
2Phase 3 trial of everolimus for metastatic renal cell carcinoma2010 · 1,144 citations
3Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).2010 · 61 citations
4RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer2011 · 1,062 citations
5Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer2006 · 106 citations